Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 51 to 75 of 2489

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Suspected cancer: recognition and referralNG12
Slide sheets for moving or repositioning a person: late-stage assessmentHTE23
Falls: assessment and prevention in older people and in people 50 and over at higher riskNG249
FallsQS86
Leniolisib for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and overHST33
Tislelizumab in combination for untreated advanced non-small-cell lung cancer (terminated appraisal)TA1058
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labourIPG800
Robot-assisted surgery for soft tissue procedures: early value assessmentHTE21
Robot-assisted surgery for orthopaedic procedures: early value assessmentHTE22
Rucaparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapyTA1055
Molnupiravir for treating COVID-19TA1056
Relugolix–estradiol–norethisterone for treating symptoms of endometriosisTA1057
Cladribine for treating active relapsing forms of multiple sclerosisTA1053
Ruxolitinib for treating acute graft versus host disease that responds inadequately to corticosteroids in people 12 years and overTA1054
Early and locally advanced breast cancer: diagnosis and managementNG101
Burosumab for treating X-linked hypophosphataemia in children and young peopleHST8
Olipudase alfa for treating acid sphingomyelinase deficiency (Niemann–Pick disease) type AB and type BHST32
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A in people 2 years and overTA1051
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer (terminated appraisal)TA1052
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after first-line chemoimmunotherapy when a stem cell transplant is suitableTA1048
Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive minimal residual disease-negative B-cell precursor acute lymphoblastic leukaemiaTA1049
Fenfluramine for treating seizures associated with Lennox–Gastaut syndrome in people 2 years and overTA1050
Zolbetuximab with chemotherapy for untreated claudin-18.2-positive HER2-negative unresectable advanced gastric or gastro-oesophageal junction adenocarcinomaTA1046
Atezolizumab for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is unsuitable (terminated appraisal)TA1047
Alcohol-mediated perivascular renal sympathetic denervation for resistant hypertensionIPG801

Results per page

  1. 10
  2. 25
  3. 50
  4. All